Results 11 to 20 of about 115,105 (360)
Clinical Infectious Diseases, 2020 Background The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection.
Xueting Yao +14 more
semanticscholar +1 more source
Unmet needs and future perspectives in hydroxychloroquine retinopathy
Frontiers in Medicine, 2023 Retinopathy is a well-recognized toxic effect of hydroxychloroquine treatment. As hydroxychloroquine retinopathy is potentially a vision-threatening condition, early detection is imperative to minimize vision loss due to drug toxicity.
Imran H. Yusuf +2 more
doaj +1 more source
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
New England Journal of Medicine, 2020 Background Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. Methods We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New ...
J. Geleris +11 more
semanticscholar +1 more source
COVID-19 and chronological aging : senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? [PDF]
, 2020 COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family.
Auwerx +30 more
core +2 more sources
BMC Infectious Diseases, 2021 Background Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective ...
Andrew Ip +24 more
doaj +1 more source
Cell Discovery, 2020 Dear Editor, The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) poses a serious threat to global public health and local economies.
Jia Liu +9 more
semanticscholar +1 more source
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
New England Journal of Medicine, 2020 Background Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine.
D. Boulware +23 more
semanticscholar +1 more source
Hydroxychloroquine in nephrology: current status and future directions [PDF]
JN. Journal of Nephrology (Milano. 1992), 2023 Hydroxychloroquine is one of the oldest disease-modifying anti-rheumatic drugs in clinical use. The drug interferes with lysosomal activity and antigen presentation, inhibits autophagy, and decreases transcription of pro-inflammatory cytokines.
Indu Ramachandra Rao +6 more
openalex +2 more sources
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
medRxiv, 2020 Aims: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited.
Zhaowei Chen +8 more
semanticscholar +1 more source
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
New England Journal of Medicine, 2020 Background Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited.
A. Cavalcanti +34 more
semanticscholar +1 more source